References

Anderson GL, Limacher M. Effects of Conjugated Equine Estrogen in Postmenopausal Women with Hysterectomy: The Women's Health Initiative Randomized Controlled Trial. J Am Med Assoc.. 2004; https://doi.org/10.1001/jama.291.14.1701

Bakken K, Alsaker E, Eggen AE, Lund E. Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study. International Journal of Cancer.. 2004; 112:(1)130-134 https://doi.org/10.1002/ijc.20389

Bao TZ, Han GZ, Shim JY Quantitative structure-activity relationship of various endogenous estrogen metabolites for human estrogen receptor α and β subtypes: Insights into the structural determinants favoring a differential subtype binding. Endocrinology. 2006; https://doi.org/10.1210/en.2006-0113

Chlebowski RT, Hendrix SL, Langer RD Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA.. 2003; 289:(24)3243-3253 https://doi.org/10.1001/jama.289.24.3243

Cummings JA, Brizendine L. Comparison of physical and emotional side effects of progesterone or medroxyprogesterone in early postmenopausal women. Menopause.. 2002; 9:(4)253-263 https://doi.org/10.1097/00042192-200207000-00006

Fitzpatrick LA, Pace C, Wiita B. Comparison of Regimens Containing Oral Micronized Progesterone or Medroxyprogesterone Acetate on Quality of Life in Postmenopausal Women: A Cross-Sectional Survey. Journal of Women's Health & Gender-Based Medicine.. 2000; 9:(4)381-387 https://doi.org/10.1089/15246090050020691

Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Research and Treatment.. 2007; 107:(1)103-111 https://doi.org/10.1007/s10549-007-9523-x

Greendale GA, Reboussin BA, Hogan P, Barnabei VM, Shumaker S, Johnson S, Barrett-Connor E. Symptom relief and side effects of postmenopausal hormones: Results from the postmenopausal estrogen/progestin interventions 8.Greendale G. Symptom relief and side effects of postmenopausal hormones: results from the postmenopausal estrogen/progestin interventions trial. Obstetrics & Gynecology.. 1998; 92:(6)982-988 https://doi.org/10.1016/s0029-7844(98)00305-6

Greene JG. A factor analytic study of climacteric symptoms. Journal of Psychosomatic Research.. 1976; 20:(5)425-430 https://doi.org/10.1016/0022-3999(76)90005-2

Holtorf K. The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy?. Postgraduate medicine.. 2009; 121:(1)73-85 https://doi.org/10.3810/pgm.2009.01.1949

Judd Meoane-Sims I. Effects of hormone replacement therapy on endometrial histology in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. J Am Med Assoc.. 1996; https://doi.org/10.1001/jama.275.5.370

Leonetti H. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstetrics & Gynecology.. 1999; 94:(2)225-228 https://doi.org/10.1016/s0029-7844(99)00266-5

Lewis JE, Hilditch JR, Wong CJ. Further psychometric property development of the Menopause-Specific Quality of Life questionnaire and development of a modified version, MENQOL-Intervention questionnaire. Maturitas.. 2005; 50:(3)209-221 https://doi.org/10.1016/j.maturitas.2004.06.015

Lindenfeld EA, Langer RD. Bleeding Patterns of the Hormone Replacement Therapies in the Postmenopausal Estrogen and Progestin Interventions Trial. Obstetrics & Gynecology. 2003; 101:(5, Part 1)1020-1021 https://doi.org/10.1097/00006250-200305000-00041

Mueck AO. Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone. Climacteric. 2012; 15:11-17 https://doi.org/10.3109/13697137.2012.669624

Paech K. Differential Ligand Activation of Estrogen Receptors ER and ER at AP1 Sites. Science. 1997; 277:(5331)1508-1510 https://doi.org/10.1126/science.277.5331.1508

Panay N. Body identical hormone replacement. Post Reproductive Health.. 2014; 20:(2)69-72 https://doi.org/10.1177/2053369114536672

Panay N, Fenton A. Bioidentical hormones: what is all the hype about?. Climacteric.. 2010; 13:(1)1-3 https://doi.org/10.3109/13697130903550250

Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC. Estrogen Receptor – Inhibits Human Breast Cancer Cell Proliferation and Tumor Formation by Causing a G2Cell Cycle Arrest. Cancer Research.. 2004; 64:(1)423-428 https://doi.org/10.1158/0008-5472.can-03-2446

Rossouw J, Anderson G, Prentice R Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial. JAMA: The Journal of the American Medical Association.. 2002; 288:(3)321-333 https://doi.org/10.1001/jama.288.3.321

Ruiz AD, Daniels KR, Barner JC, Carson JJ, Frei CR. Effectiveness of Compounded Bioidentical Hormone Replacement Therapy: An Observational Cohort Study. BMC Women's Health.. 2011; 11:(1) https://doi.org/10.1186/1472-6874-11-27

Simon JA. What's new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone. Climacteric. 2012; 15:3-10 https://doi.org/10.3109/13697137.2012.669332

Simon JA, Kaunitz AM, Kroll R, Graham S, Bernick B, Mirkin S. Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms. Menopause.. 2019; 26:(5)506-512 https://doi.org/10.1097/gme.0000000000001271

Thompson JJ, Ritenbaugh C, Nichter M. Why women choose compounded bioidentical hormone therapy: lessons from a qualitative study of menopausal decision-making. BMC Women's Health. 2017; 17:(1) https://doi.org/10.1186/s12905-017-0449-0

Compounded bioidentical HRT improves quality of life and reduces menopausal symptoms

02 July 2020
Volume 2 · Issue 7

Abstract

Bioidentical hormone replacement therapy, a form of hormone balancing and treatment that uses hormones identical to the ones naturally produced by the body, is an effective and well-tolerated method of hormone replacement therapy. The Marion Gluck Clinic conducted a small-scale study to assess the effectiveness of compounded bioidentical hormone replacement therapy treatment protocols and their impact on the quality of life of women experiencing symptoms of the menopause. Quality of life was assessed by completing the Greene Climacteric Scale questionnaire before and after bioidentical hormone replacement therapy treatment. Statistical significance of the data was tested using a Student's two-tailed, paired t-test. The results demonstrated a significant improvement of 52% in quality of life after bioidentical hormone replacement therapy treatment. All 21 menopausal symptoms assessed were greatly reduced after BHRT treatment. Evidence is provided showing that bioidentical hormone replacement therapy, performed according to the Marion Gluck Clinic local clinical guidelines, improves quality of life and reduces menopause-associated symptoms in women. In addition, this pilot study paves the way for a future full-scale study, where the authors aim to assess quality of life and safety in a significantly larger number of women.

Hormone balancing using bioidentical hormone replacement therapy (BHRT) is a form of treatment that uses hormones with an identical molecular structure to the hormones naturally produced by the body, such as progesterone, estradiol and estriol, as opposed to non-bioidentical hormones that are structurally different from human hormones, such as conjugated equine estrogen (CEE) and synthetic progestins such as medroxyprogesterone (MPA).

Data from clinical outcomes and physiological studies demonstrate that bioidentical hormones are effective and produce fewer side effects than their non-bioidentical counterparts, including a lower risk of breast cancer and cardiovascular disease (Fournier et al, 2005; Fournier et al, 2007; Holtorf, 2009).

As an example, progesterone, when compared with synthetic progestins, is associated with better clinical outcomes. Studies where women on hormone replacement therapy (HRT) were switched from synthetic progestins to progesterone reported greater satisfaction, better quality of life (QoL), and fewer side effects (Greendale et al, 1998; Fitzpatrick et al, 2000; Cummings and Brizendine, 2002; Lindenfeld and Langer, 2002). It is important to note that natural progesterone is reported to be as effective as synthetic progestins in protecting the endometrium from hyperplastic changes associated with estrogen-only therapy (Judd and Meoane-Sims, 1996).

Register now to continue reading

Thank you for visiting Journal of Prescribing Practice and reading some of our peer-reviewed resources for prescribing professionals. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to our clinical or professional articles

  • New content and clinical newsletter updates each month